VCANBIO(600645)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥391,700,257.34, representing an increase of 11.95% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2021 was ¥80,118,557.13, reflecting a significant increase of 54.74% year-over-year[7]. - The basic earnings per share for Q3 2021 was ¥0.17, up by 54.55% year-over-year[10]. - Net profit for the third quarter of 2021 was ¥194,586,517.04, compared to ¥133,093,977.65 in the previous year, indicating a growth of 46.1%[33]. - The company reported a profit before tax of ¥259,681,320.22, up from ¥170,448,436.72, representing a growth of 52.2%[33]. - Total comprehensive income for the period was CNY 186,621,508.15, a decrease from CNY 283,669,410.36 in the previous period[35]. - Basic and diluted earnings per share increased to CNY 0.41 from CNY 0.28 year-over-year[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,180,605,540.72, an increase of 6.17% from the end of the previous year[10]. - The total assets of the company were reported at ¥5,180,605,540.72, an increase from ¥4,879,569,536.17 year-over-year[24]. - Current liabilities totaled ¥1,382,441,046.85, compared to ¥1,300,015,430.19 in the previous year, showing an increase of approximately 6.3%[24]. - The company's total liabilities increased to ¥1,493,581,632.30 from ¥1,377,191,804.90, showing a rise of 8.4%[26]. - The total equity attributable to shareholders of the parent company rose to ¥3,586,855,067.12, up from ¥3,396,348,979.10, marking an increase of 5.6%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥232,588,634.00, reflecting a year-over-year increase of 53.40%[10]. - Cash inflow from operating activities totaled CNY 1,245,397,088.82, up from CNY 1,060,592,301.77 in the previous year[39]. - Net cash flow from operating activities was CNY 232,588,634.00, compared to CNY 151,618,311.80 in the same period last year[39]. - Cash outflow from investment activities was CNY 164,292,903.89, significantly lower than CNY 735,223,631.40 in the previous year[39]. - Net cash flow from investment activities was negative CNY 92,456,340.77, compared to a positive CNY 306,040,337.65 in the previous year[39]. - Total cash inflow from financing activities was CNY 692,100.00, down from CNY 35,876,865.61 in the previous year[39]. - Net cash flow from financing activities was negative CNY 21,937,567.81, compared to negative CNY 72,575,923.72 in the previous year[39]. Shareholder Information - The company reported a total of 38,203 common shareholders at the end of the reporting period[14]. - The major shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares[14]. Investments and Expenses - Research and development expenses for the third quarter were ¥102,165,541.66, compared to ¥93,035,969.44 in the same quarter of 2020, reflecting a 9.1% increase[29]. - The company attributed the increase in net profit to the fair value gains from the fund shares held by its foreign subsidiary Aceso[13]. - Total operating costs amounted to ¥1,000,760,328.15, up from ¥857,674,929.78, reflecting a significant increase in expenses[29]. Other Financial Metrics - The weighted average return on equity for Q3 2021 was 2.22%, an increase of 0.79 percentage points compared to the same period last year[10]. - The deferred income tax liabilities increased significantly to ¥35,481,489.27 from ¥14,405,856.03, indicating a rise of 146.5%[26]. - The company recorded a decrease in other comprehensive income after tax, amounting to -¥7,965,008.89, compared to an increase of ¥150,575,432.71 in the previous year[33]. - The company reported a decrease in inventory, which stood at ¥217,958,041.29, down from ¥222,395,516.19[21]. - The company's goodwill remained stable at ¥722,634,814.15, unchanged from the previous year[24].